Share this article
Tech Mahindra Joins StaTwig in Global Vaccine-Tracing Blockchain
The firms say the blockchain can improve transparency and prevent failures in global vaccine supply chains.
Updated Sep 14, 2021, 1:20 p.m. Published Jul 5, 2021, 11:18 a.m.
Make us preferred on Google
Indian IT giant Tech Mahindra is working with blockchain startup StaTwig on a blockchain-based product for tracing global vaccine supply chains.
STORY CONTINUES BELOW
Don't miss another story.Subscribe to the Crypto Daybook Americas Newsletter today. See all newsletters
- The IT firm said Monday the VaccineLedger blockchain is designed to improve transparency and prevent failures in vaccine supply, including the distribution of expired vaccines, stock depletion and counterfeiting.
- Tech Mahindra, a subsidiary of Indian conglomerate Mahindra Group, has joined with StaTwig, a startup based in Hyderabad and Singapore. The company created the system to trace vaccines from manufacturers to consumers.
- In the statement, the companies did not say when the product was likely to become available.
- The two will work to create a global network of vaccine researchers, governments, pharmaceutical companies, distributors and health-care workers, according to the announcement.
- This is not the first time Tech Mahindra has shown interest in blockchain solutions. Last year, it began working with local edutech firm Idealabs to develop blockchain talent in India, and later announced it will offer blockchain solutions to global customers using Amazon Web Services (AWS).
More For You
More For You
Mike McGlone softens bitcoin downside target to $28,000 after backlash over $10,000 call
Market analysts said the extreme downside scenario risked influencing real capital flows, prompting a heated public debate over bitcoin’s macro outlook.
What to know:
- Bloomberg Intelligence analyst Mike McGlone has shifted his bitcoin downside target from $10,000 to about $28,000 after criticism that his earlier call was alarmist and risky for investors.
- McGlone now argues that $28,000 is a more probable level based on historical price distribution and maintains that his analysis shows why investors should avoid bitcoin and other risk assets.
- Critics including Jason Fernandes and Mati Greenspan say the revised $28,000 target is still unlikely or overly deterministic, warning that such stark forecasts can distort positioning and put real capital at risk in reflexive crypto markets.
Top Stories
